Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNOTIME timing of pembrolizumab with carboplatin + pemetrexed in first-line metastatic non-squamous NSCLC
2025-521891-78-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, carboplatin and pemetrexed in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: 1-year milestone survival rate. Planned start May 2026; status: authorised.
02
Drugs
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2025-521891-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521891-78-00.